Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy

T. S. Herman, L. H. Einhorn, S. E. Jones, C. Nagy, A. B. Chester, J. C. Dean, B. Furnas, S. D. Williams, S. A. Leigh, Robert T Dorr, T. E. Moon

Research output: Contribution to journalArticle

149 Citations (Scopus)

Abstract

Two double-blind, crossover trials comparing the antiemetic effectiveness of nabilone, a new synthetic cannabinoid, with that of prochlorperazine were conducted in patients with severe nausea and vomiting associated with anticancer chemotherapy. Of 113 patients evaluated, 90 (80%) responded to nabilone therapy, whereas only 36 (32%) responded to prochlorperazine (P<0.001). Complete relief of symptoms was infrequent, occurring only in nine patients (8%) given nabilone. When both drugs were compared both nausea (P<0.01) and vomiting episodes (P<0.001) were significantly lower in patients given nabilone. Moreover, patients clearly favored nabilone for continued use (P<0.001). Predominant side effects noted by patients were similar for both agents and included somnolence, dry mouth and dizziness but were about twice as frequent and more often severe in patients receiving nabilone. In addition, four patients (3%) taking nabilone had side effects (hallucinations in three, hypotension in one) that required medical attention. Euphoria associated with nabilone was infrequent (16%) and mild.

Original languageEnglish (US)
Pages (from-to)1295-1297
Number of pages3
JournalNew England Journal of Medicine
Volume300
Issue number23
StatePublished - 1979

Fingerprint

Prochlorperazine
Antiemetics
Drug Therapy
Neoplasms
Nausea
Vomiting
Cannabinoids
nabilone
Hallucinations
Dizziness
Hypotension
Cross-Over Studies
Mouth

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Herman, T. S., Einhorn, L. H., Jones, S. E., Nagy, C., Chester, A. B., Dean, J. C., ... Moon, T. E. (1979). Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. New England Journal of Medicine, 300(23), 1295-1297.

Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. / Herman, T. S.; Einhorn, L. H.; Jones, S. E.; Nagy, C.; Chester, A. B.; Dean, J. C.; Furnas, B.; Williams, S. D.; Leigh, S. A.; Dorr, Robert T; Moon, T. E.

In: New England Journal of Medicine, Vol. 300, No. 23, 1979, p. 1295-1297.

Research output: Contribution to journalArticle

Herman, TS, Einhorn, LH, Jones, SE, Nagy, C, Chester, AB, Dean, JC, Furnas, B, Williams, SD, Leigh, SA, Dorr, RT & Moon, TE 1979, 'Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy', New England Journal of Medicine, vol. 300, no. 23, pp. 1295-1297.
Herman TS, Einhorn LH, Jones SE, Nagy C, Chester AB, Dean JC et al. Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. New England Journal of Medicine. 1979;300(23):1295-1297.
Herman, T. S. ; Einhorn, L. H. ; Jones, S. E. ; Nagy, C. ; Chester, A. B. ; Dean, J. C. ; Furnas, B. ; Williams, S. D. ; Leigh, S. A. ; Dorr, Robert T ; Moon, T. E. / Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy. In: New England Journal of Medicine. 1979 ; Vol. 300, No. 23. pp. 1295-1297.
@article{1f107bc07cbc4a0899cc7ec11c39d161,
title = "Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy",
abstract = "Two double-blind, crossover trials comparing the antiemetic effectiveness of nabilone, a new synthetic cannabinoid, with that of prochlorperazine were conducted in patients with severe nausea and vomiting associated with anticancer chemotherapy. Of 113 patients evaluated, 90 (80{\%}) responded to nabilone therapy, whereas only 36 (32{\%}) responded to prochlorperazine (P<0.001). Complete relief of symptoms was infrequent, occurring only in nine patients (8{\%}) given nabilone. When both drugs were compared both nausea (P<0.01) and vomiting episodes (P<0.001) were significantly lower in patients given nabilone. Moreover, patients clearly favored nabilone for continued use (P<0.001). Predominant side effects noted by patients were similar for both agents and included somnolence, dry mouth and dizziness but were about twice as frequent and more often severe in patients receiving nabilone. In addition, four patients (3{\%}) taking nabilone had side effects (hallucinations in three, hypotension in one) that required medical attention. Euphoria associated with nabilone was infrequent (16{\%}) and mild.",
author = "Herman, {T. S.} and Einhorn, {L. H.} and Jones, {S. E.} and C. Nagy and Chester, {A. B.} and Dean, {J. C.} and B. Furnas and Williams, {S. D.} and Leigh, {S. A.} and Dorr, {Robert T} and Moon, {T. E.}",
year = "1979",
language = "English (US)",
volume = "300",
pages = "1295--1297",
journal = "New England Journal of Medicine",
issn = "0028-4793",
publisher = "Massachussetts Medical Society",
number = "23",

}

TY - JOUR

T1 - Superiority of nabilone over prochlorperazine as an antiemetic in patients receiving cancer chemotherapy

AU - Herman, T. S.

AU - Einhorn, L. H.

AU - Jones, S. E.

AU - Nagy, C.

AU - Chester, A. B.

AU - Dean, J. C.

AU - Furnas, B.

AU - Williams, S. D.

AU - Leigh, S. A.

AU - Dorr, Robert T

AU - Moon, T. E.

PY - 1979

Y1 - 1979

N2 - Two double-blind, crossover trials comparing the antiemetic effectiveness of nabilone, a new synthetic cannabinoid, with that of prochlorperazine were conducted in patients with severe nausea and vomiting associated with anticancer chemotherapy. Of 113 patients evaluated, 90 (80%) responded to nabilone therapy, whereas only 36 (32%) responded to prochlorperazine (P<0.001). Complete relief of symptoms was infrequent, occurring only in nine patients (8%) given nabilone. When both drugs were compared both nausea (P<0.01) and vomiting episodes (P<0.001) were significantly lower in patients given nabilone. Moreover, patients clearly favored nabilone for continued use (P<0.001). Predominant side effects noted by patients were similar for both agents and included somnolence, dry mouth and dizziness but were about twice as frequent and more often severe in patients receiving nabilone. In addition, four patients (3%) taking nabilone had side effects (hallucinations in three, hypotension in one) that required medical attention. Euphoria associated with nabilone was infrequent (16%) and mild.

AB - Two double-blind, crossover trials comparing the antiemetic effectiveness of nabilone, a new synthetic cannabinoid, with that of prochlorperazine were conducted in patients with severe nausea and vomiting associated with anticancer chemotherapy. Of 113 patients evaluated, 90 (80%) responded to nabilone therapy, whereas only 36 (32%) responded to prochlorperazine (P<0.001). Complete relief of symptoms was infrequent, occurring only in nine patients (8%) given nabilone. When both drugs were compared both nausea (P<0.01) and vomiting episodes (P<0.001) were significantly lower in patients given nabilone. Moreover, patients clearly favored nabilone for continued use (P<0.001). Predominant side effects noted by patients were similar for both agents and included somnolence, dry mouth and dizziness but were about twice as frequent and more often severe in patients receiving nabilone. In addition, four patients (3%) taking nabilone had side effects (hallucinations in three, hypotension in one) that required medical attention. Euphoria associated with nabilone was infrequent (16%) and mild.

UR - http://www.scopus.com/inward/record.url?scp=0018747577&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018747577&partnerID=8YFLogxK

M3 - Article

C2 - 375088

AN - SCOPUS:0018747577

VL - 300

SP - 1295

EP - 1297

JO - New England Journal of Medicine

JF - New England Journal of Medicine

SN - 0028-4793

IS - 23

ER -